Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. ("Sanyou Bio") and South Korea's FatiAbGen Co., Ltd.  jointly announced the signing of a comprehensive strategic collaboration agreement covering joint project development, exclusive representation in the Korean market, and global market expansion.

This partnership leverages Sanyou Bio's globally leading AI-STAL drug discovery platform and FatiAbGen's deep local presence in South Korea to drive synergistic growth across Korea, Europe, and beyond — empowering biotech innovators worldwide.

The strategic alliance defines a three-pronged cooperation framework:

1. The two companies will initiate in-depth R&D collaboration around a specific drug discovery project;

2. FatiAbGen will serve as Sanyou Bio's official partner in South Korea, fully representing Sanyou's integrated drug discovery services and products powered by the "AI-STAL Super Trillion Antibody Library";

3. Both parties will jointly integrate global resources to expand into the international biopharma market — including Europe — providing world-class R&D solutions to overseas innovative drug developers. To ensure a smooth rollout of the partnership, the FatiAbGen team was invited to visit Sanyou Bio's R&D facilities following the signing ceremony. They also participated in a customized technical training program, equipping them with comprehensive knowledge of Sanyou's service portfolio and cutting-edge technologies — enabling FatiAbGen to deliver professional and precise technical support to Korean clients.

JayJay Lee, CEO of FatiAbGen, commented: "We are honored to form a strategic partnership with Sanyou Bio, a global pioneer in new drug discovery. Sanyou's world-class technology platform and integrated solutions perfectly address the early-stage R&D gaps faced by many Korean biotech companies. Through this collaboration, we aim to introduce top-tier R&D capabilities to Korea, empowering local innovators and accelerating the creation of globally competitive new drugs."

Dr. Guojun Lang, CEO of Sanyou Bio, added: "Our collaboration with FatiAbGen marks a key milestone in Sanyou's globalization strategy. The FatiAbGen team's deep market insights and exceptional professionalism have laid a solid foundation of mutual trust. We firmly believe that by combining our 'Innovation Hub For Originating Drug Discovery' model with localized professional services, we can swiftly respond to Korean clients' needs: co-creating a dynamic regional innovation ecosystem with FatiAbGen and bringing new hope to patients in Korea and around the world."

This partnership represents a significant step forward in Sanyou Bio's global expansion. The partnership reflects both companies' unwavering commitment to shared growth and underscores Sanyou's strategic vision to empower local partners and drive a new wave of global biopharmaceutical innovation.